Grünenthal and BCWorld Pharm Join Forces for Niche Pain Management Solution in South Korea
In a significant move for the pharmaceutical industry, Grünenthal, a globally recognized leader in pain management, has aligned with BCWorld Pharm Co., Ltd., a growing specialty pharmaceutical company in South Korea. This partnership promises to reshape the pain management landscape in Asia by granting BCWorld the exclusive rights to Qutenza®, a non-opioid topical patch treatment designed to alleviate peripheral neuropathic pain.
The agreement, announced on March 5, 2026, marks a crucial step in Grünenthal's mission to broaden the reach of Qutenza® into the Asia-Pacific market. By partnering with BCWorld Pharm, Grünenthal aims to ensure that patients in South Korea gain access to innovative alternatives to opioid treatments, a growing concern in global health management. Jan Adams, the Chief Commercial Officer at Grünenthal, expressed enthusiasm about this collaboration, citing it as an essential part of their strategy to enhance their offerings and deliver a world free of pain:
Embedded within this agreement is the responsibility placed upon BCWorld Pharm to secure marketing authorizations for Qutenza® in South Korea. Upon approval, which is anticipated in the near future, BCWorld will oversee the marketing and distribution efforts for the product. This signifies a well-structured plan that promises to integrate Qutenza into the fabric of South Korea's pain management system effectively.
Steve Hong, the CEO of BCWorld Pharm, reflected on the partnership, emphasizing its core mission:
For Grünenthal, this initiative aligns with their broader vision, which has seen significant success in recent years. Acquiring global rights to Qutenza® in 2018 was a pivotal move in their MA-driven growth strategy. Over the past years, the company has completed multiple acquisitions totaling over €2.3 billion, effectively enhancing their portfolio and profitability.
Qutenza®, a topical system that utilizes an 8% capsaicin formulation, is accepted in the US for treating neuropathic pain resulting from conditions such as postherpetic neuralgia and diabetic peripheral neuropathy. This aspect of the product adds a layer of credibility and effectiveness, making it a valuable addition to BCWorld's offerings.
In conclusion, this collaboration promises to pave the way for an enhanced approach to pain management in South Korea, marking a significant development for both companies involved. The partnership embodies a shared commitment to innovation and patient care, potentially setting a precedent for how non-opioid treatments can be scaled and adopted in Asia.
For those seeking more information on Qutenza® and its benefits, additional resources can be found on the Grünenthal and BCWorld Pharm websites. This partnership not only highlights the strategic expansions of both companies but also serves as a vital step towards addressing the global challenge of pain management, supporting a future where effective relief is accessible to all patients in need.
The agreement, announced on March 5, 2026, marks a crucial step in Grünenthal's mission to broaden the reach of Qutenza® into the Asia-Pacific market. By partnering with BCWorld Pharm, Grünenthal aims to ensure that patients in South Korea gain access to innovative alternatives to opioid treatments, a growing concern in global health management. Jan Adams, the Chief Commercial Officer at Grünenthal, expressed enthusiasm about this collaboration, citing it as an essential part of their strategy to enhance their offerings and deliver a world free of pain:
"We are executing on a dedicated strategy to bring Qutenza® into the Asia-Pacific region to facilitate greater access to non-opioid treatment options for people living with pain and expand the brand's global footprint."
Embedded within this agreement is the responsibility placed upon BCWorld Pharm to secure marketing authorizations for Qutenza® in South Korea. Upon approval, which is anticipated in the near future, BCWorld will oversee the marketing and distribution efforts for the product. This signifies a well-structured plan that promises to integrate Qutenza into the fabric of South Korea's pain management system effectively.
Steve Hong, the CEO of BCWorld Pharm, reflected on the partnership, emphasizing its core mission:
"Expanding access to innovative, non-opioid treatment options for patients with neuropathic pain is central to our mission of 'Commit to a Better Future for Patients.' Our partnership with Grünenthal enables us to introduce Qutenza® to South Korea while further diversifying and strengthening our pain management portfolio."
For Grünenthal, this initiative aligns with their broader vision, which has seen significant success in recent years. Acquiring global rights to Qutenza® in 2018 was a pivotal move in their MA-driven growth strategy. Over the past years, the company has completed multiple acquisitions totaling over €2.3 billion, effectively enhancing their portfolio and profitability.
Qutenza®, a topical system that utilizes an 8% capsaicin formulation, is accepted in the US for treating neuropathic pain resulting from conditions such as postherpetic neuralgia and diabetic peripheral neuropathy. This aspect of the product adds a layer of credibility and effectiveness, making it a valuable addition to BCWorld's offerings.
In conclusion, this collaboration promises to pave the way for an enhanced approach to pain management in South Korea, marking a significant development for both companies involved. The partnership embodies a shared commitment to innovation and patient care, potentially setting a precedent for how non-opioid treatments can be scaled and adopted in Asia.
For those seeking more information on Qutenza® and its benefits, additional resources can be found on the Grünenthal and BCWorld Pharm websites. This partnership not only highlights the strategic expansions of both companies but also serves as a vital step towards addressing the global challenge of pain management, supporting a future where effective relief is accessible to all patients in need.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.